- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT06800313
전이성 거세 저항성 전립선 암 환자의 HLD-0915 연구 (MCRPC)
전이성 거세 저항성 전립선 암 환자에서 HLD-0915의 1/2 연구 (MCRPC)
Assessment of the safety and efficacy of HLD-0915 (JNJ-101556143) in patients with metastatic prostate cancer who have progressed on prior systemic therapies, with further evaluation in additional prostate cancer populations.
연구 개요
상태
정황
연구 유형
등록 (추정된)
단계
- 2 단계
- 1단계
연락처 및 위치
연구 연락처
- 이름: Study Contact
- 전화번호: 844-434-4210
- 이메일: Participate-In-This-Study1@its.jnj.com
연구 장소
-
-
Colorado
-
Colorado Springs, Colorado, 미국, 80909
- 모병
- Rocky Mountain Cancer Center
-
Denver, Colorado, 미국, 80218
- 모병
- Sarah Cannon Research Institute 1
-
-
Connecticut
-
New Haven, Connecticut, 미국, 06511
- 모병
- Yale University
-
-
Florida
-
Sarasota, Florida, 미국, 34232
- 모병
- Florida Cancer Specialists
-
-
Louisiana
-
Metairie, Louisiana, 미국, 70006
- 모병
- XCancer Research Network LCMC Health EJGH
-
-
Massachusetts
-
Boston, Massachusetts, 미국, 02114
- 모병
- Dana Farber Mass General Brigham Cancer Care Inc
-
-
Michigan
-
Grand Rapids, Michigan, 미국, 49546
- 모병
- South Texas Accelerated Research Therapeutics, LLC (START)
-
-
Nebraska
-
Omaha, Nebraska, 미국, 68130
- 모병
- Urology Cancer Center, PC
-
-
New York
-
Long Island City, New York, 미국, 11101
- 모병
- Memorial Sloan Kettering Cancer Center
-
Syracuse, New York, 미국, 13210
- 모병
- Associated Medical Professionals
-
-
North Carolina
-
Durham, North Carolina, 미국, 27710
- 모병
- Duke University Medical Center
-
-
South Carolina
-
Myrtle Beach, South Carolina, 미국, 29572
- 모병
- Carolina Urologic Research Center
-
-
Tennessee
-
Nashville, Tennessee, 미국, 37203
- 모병
- Sarah Cannon Research Institute
-
Nashville, Tennessee, 미국, 37209
- 모병
- Urology Associates
-
-
Texas
-
Austin, Texas, 미국, 78758
- 모병
- NEXT Oncology
-
Houston, Texas, 미국, 77030
- 모병
- MD Anderson Cancer Center
-
-
Virginia
-
Norfolk, Virginia, 미국, 23502
- 모병
- Virginia Clinical Research
-
-
-
-
-
Sutton, 영국, SM2 5PT
- 모병
- The Royal Marsden NHS Trust
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Patients must meet the following criteria to be eligible study participation:
Key Inclusion Criteria:
All Study Arms (Phase 1 Part 1 & 2, Phase 2 Part 1, Part 2A, 2B, 2C & 2D):
Males ≥ 18 years old Histological, pathological, and/or cytological confirmation of prostate adenocarcinoma Adequate hematological, renal, and hepatic function. Able to swallow oral medication
mCRPC Arms: (Phase 1 Part 1 & 2, Phase 2 Part 1): Prior orchiectomy or ongoing androgen-deprivation therapy and a castrate level of serum testosterone Progressive mCRPC defined as having demonstrated PSA progression on the prior regimen
SOAR Arm (Phase 2 Part 2A) mHSPC with distant metastatic disease based on conventional imaging PSA ≥0.2 ng/mL, following treatment with next generation ARPI for at least 180 days and up to 365 days No evidence of radiographic or PSA progression while receiving ARPI
mHSPC arms (Phase 2 Part 2B, 2C & 2D) serum testosterone >150ng/ml mHSPC with distant metastatic disease based on conventional imaging and PSA >2.0 ng/mL
Key Exclusion Criteria:
All arms (Phase 1 Part 1 & 2, Phase 2 Part 1, Part 2A, 2B, 2C & 2D):
Has experienced a recent major bleed or has a known bleeding disorder Tumors exhibiting neuroendocrine or small cell carcinoma component by histopathology Receiving continuous corticosteroids at prednisone-equivalent dose of >10 mg/day Prior or ongoing significant medical condition
mCRPC arms: (Phase 1 Part 1 & 2, Phase 2 Part 1): Has received systemic anti-cancer therapy or investigational drugs within 2 weeks prior to first dose of study drug with certain exceptions requiring longer washout periods
SOAR arm (Phase 2 Part 2A) Has received any prior cytotoxic chemotherapy for prostate cancer
mHSPC arms (Phase 2 Part 2B, 2C & 2D) regional pelvic lymph node disease only
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위화되지 않음
- 중재 모델: 순차적 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: JNJ-101556143 Phase 1 Part 1 - Dose Escalation
Treatment cycle consists of 21 days. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.) |
Experimental: Oral JNJ-101556143 |
|
실험적: JNJ-101556143 Phase 1 Part 2 - Formulation Exploration
Treatment cycle consists of 21 days. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.) |
Experimental: Oral JNJ-101556143 Experimental: Oral JNJ-101556143 Experimental: Oral JNJ-101556143 |
|
실험적: JNJ-101556143 Phase 2 Part 1 - Dose Optimization
Treatment cycle consists of 21 days. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.) |
Experimental: Oral JNJ-101556143 |
|
실험적: Phase 2 Part 2A - SOAR
Treatment cycle consists of 21 days. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.) |
Experimental: Oral JNJ-101556143 |
|
실험적: Phase 2 Part 2B - HSPC Expansion
Treatment cycle consists of 21 days. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.) |
Experimental: Oral JNJ-101556143 |
|
실험적: Phase 2 Part 2C - HSPC Expansion
Treatment cycle consists of 21 days. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.) |
Experimental: Oral JNJ-101556143 |
|
실험적: Phase 2 Part 2D - HSPC Expansion
Treatment cycle consists of 21 days. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.) |
Experimental: Oral JNJ-101556143 |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
기간 |
|---|---|
|
Frequency of dose-limiting toxicities (DLTs)
기간: 21 days
|
21 days
|
|
Frequency and severity of AEs and abnormal ECG, laboratory and clinical changes since baseline
기간: 21 days
|
21 days
|
|
Phase 1 Part 2 (formulation exploration) relative bioavailability
기간: 22 days
|
22 days
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
PK Parameters
기간: 21 days
|
21 days
|
|
|
Duration of Response (DOR)
기간: 21 days
|
21 days
|
|
|
Radiographic Progression-Free Survival (rPFS)
기간: 63 days
|
63 days
|
|
|
Time to Response (TTR)
기간: 63 days
|
63 days
|
|
|
Change in PSA over time
기간: 21 days
|
Including PSA50 and PSA90 response |
21 days
|
|
Objective Response Rate (ORR)
기간: 63 days
|
Per RECIST in evaluable patients |
63 days
|
공동 작업자 및 조사자
수사관
- 연구 책임자: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
추가 관련 MeSH 약관
기타 연구 ID 번호
- HLD-0915-ONC-101
- HLD-0915-ONC-101 (기타 식별자: Janssen Research & Development, LLC)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .